Maxim Group upgraded shares of Palisade Bio (NASDAQ:PALI – Free Report) from a hold rating to a buy rating in a research report report published on Friday, Benzinga reports. Maxim Group currently has $1.50 price objective on the stock.
Palisade Bio Trading Down 0.8 %
Shares of Palisade Bio stock opened at $0.60 on Friday. The business has a 50-day moving average price of $0.57 and a two-hundred day moving average price of $1.15. Palisade Bio has a 1-year low of $0.50 and a 1-year high of $8.54. The company has a market cap of $5.53 million, a P/E ratio of 0.04 and a beta of 1.60.
Palisade Bio (NASDAQ:PALI – Get Free Report) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.09). Equities research analysts forecast that Palisade Bio will post -1.82 EPS for the current fiscal year.
Hedge Funds Weigh In On Palisade Bio
Palisade Bio Company Profile
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.
- Five stocks we like better than Palisade Bio
- How to Invest in Canada for Beginners
- The most upgraded stocks in November have two things in common
- Technology Stocks Explained: Here’s What to Know About Tech
- Monday.com rocked earnings like it’s the weekend
- Growth Stocks: What They Are, Examples and How to Invest
- Plan to own one retailer? Make it this one
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.